Back to today’s briefing

Story perspectives

Eli Lilly's Zepbound Boosts Psoriatic Arthritis Treatment Success

1/9/2026

31 6

Summary

Story summary

Eli Lilly reported that in a late-stage trial, 31.7% of patients receiving Zepbound with Taltz achieved at least a 50% reduction in disease activity and a 10% weight loss after 36 weeks.
Only 0.8% of patients on Taltz alone reached the same outcomes.
The study enrolled 271 overweight or obese adults with active psoriatic arthritis.
Lilly aims to raise treatment standards for psoriatic arthritis, which often coexists with obesity.

1 of 1

Story summary

Eli Lilly reported that in a late-stage trial, 31.7% of patients receiving Zepbound with Taltz achieved at least a 50% reduction in disease activity and a 10% weight loss after 36 weeks.
Only 0.8% of patients on Taltz alone reached the same outcomes.
The study enrolled 271 overweight or obese adults with active psoriatic arthritis.
Lilly aims to raise treatment standards for psoriatic arthritis, which often coexists with obesity.